News

February 21, 2018

Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018

Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018

Cytokinetics is currently conducting a Phase 2 clinical trial of CK-2127107 – now referred to by the generic name, reldesemtiv – which is designed to assess the investigational agent’s effect on multiple measures of muscle function in both ambulatory and non-ambulatory...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

February 16, 2018

Cure SMA Receives Generous Gift

Cure SMA is extremely pleased to announce a generous $620,000 gift has been made to the organization. The donation was made anonymously in honor of William N. Kanehann. Billy had SMA and died in 2013 at the age of 23. We are grateful for this amazing donation in memory of his life.

This gift will be dedicated to supporting new...

READ MORE   |  

Topics: Community & Awareness, Support & Care, Front Page News

February 14, 2018

Biogen Releases Statement on CHERISH Data and Plans for New Clinical Research

Biogen Releases Statement on CHERISH Data and Plans for New Clinical Research

Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA. 

Dear Members of the SMA community,

This past December marked one year since the FDA approval of SPINRAZA® (nusinersen), the first and only treatment...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 1 - 3 of 383  12345678910Next

© 2018 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software